Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 8/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4917565 | 1.00 | HCRTR1 (0.43) | HCRTR1HCRTR2USP30GPR119ALOX5AP | |
| SCHEMBL3919921 | 0.95 | HCRTR1 (0.48) | HCRTR1HCRTR2USP30UCHL1 | |
| SCHEMBL3919918 | 0.95 | HCRTR1 (0.48) | HCRTR1HCRTR2USP30UCHL1 | |
| SCHEMBL4914297 | 0.87 | HCRTR1 (0.47) | HCRTR1HCRTR2USP30GPR119ALOX5AP | |
| SCHEMBL4914288 | 0.87 | HCRTR1 (0.47) | HCRTR1HCRTR2USP30GPR119ALOX5AP | |
| SCHEMBL4917156 | 0.86 | HCRTR1 (0.45) | HCRTR1HCRTR2USP30GPR119GRM5 | |
| SCHEMBL4917151 | 0.86 | HCRTR1 (0.45) | HCRTR1HCRTR2USP30GPR119GRM5 | |
| SCHEMBL4917620 | 0.82 | USP30 (0.43) | HCRTR1HCRTR2USP30GPR119GRM5 | |
| SCHEMBL4917611 | 0.82 | USP30 (0.43) | HCRTR1HCRTR2USP30GPR119GRM5 | |
| SCHEMBL3916610 | 0.82 | HCRTR1 (0.53) | HCRTR1HCRTR2USP30UCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161278-A1 | 2-Azetidinyl-4-(1H-Pyrazol-3-Ylamino) Pyrimidines as Inhibitors of Insulin-Like Growth Factor-1 Receptor Activity | ASTRAZENECA AB (SE) | 2008-07-03 | — | — | US | disclosed |
| EP-1863797-A1 | 2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006100461-A1 | 2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161278-A1 | 2-Azetidinyl-4-(1H-Pyrazol-3-Ylamino) Pyrimidines as Inhibitors of Insulin-Like Growth Factor-1 Receptor Activity | IGF1R, IGFBP1, IGFBP2 | HCRTR1 3753/4885HCRTR2 3688/4885USP30 4450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.